Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
IRS2 as a driver of brain metastasis in colorectal cancer: a potential target for novel therapeutic strategies.
Neuro Oncol
January 2025
Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Background: Colorectal cancer (CRC) ranks as the fourth most common cause of brain metastasis (BM), with its incidence on the rise. However, the molecular mechanisms driving the formation of these lesions from CRC remain unclear.
Methods: We analyzed the FoundationOne genomic database, which includes over 35,000 CRC samples from both local and metastatic sites.
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice.
Clin Pharmacol Ther
January 2025
Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
The safety of systemic fluoropyrimidines (e.g., 5-fluorouracil, capecitabine) is impacted by germline genetic variants in DPYD, which encodes the dihydropyrimidine dehydrogenase (DPD) enzyme that functions as the rate-limiting step in the catabolism of this drug class.
View Article and Find Full Text PDFStage-specific characterization of "early-onset colorectal cancer": Localized and synchronous metastatic disease.
Int J Cancer
January 2025
Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Türkiye.
Early-onset colorectal cancer (EOCRC) is an alarming entity worldwide. Yet, stage-specific characteristics and prognosis in localized and synchronous metastatic EOCRC are not well-defined. Two cohorts of CRC patients (localized and synchronous metastatic) were evaluated, defining EOCRC as the diagnosis <50 years old.
View Article and Find Full Text PDFPredicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines.
Front Mol Biosci
January 2025
Faculty of Biology and Biotechnologies, National Research University Higher School of Economics, Moscow, Russia.
Introduction: Colorectal cancer (CRC) is characterized by an extremely high mortality rate, mainly caused by the high metastatic potential of this type of cancer. To date, chemotherapy remains the backbone of the treatment of metastatic colorectal cancer. Three main chemotherapeutic drugs used for the treatment of metastatic colorectal cancer are 5-fluorouracil, oxaliplatin and irinotecan which is metabolized to an active compound SN-38.
View Article and Find Full Text PDFRadioresistance in rectal cancer: can nanoparticles turn the tide?
Mol Cancer
January 2025
i3S - Instituto de Investigação e Inovação em Saúde, Universidade Do Porto, Rua Alfredo Allen 208, Porto, 4200‑135, Portugal.
Rectal cancer accounts for over 35% of the worldwide colorectal cancer burden representing a distinctive subset of cancers from those arising in the colon. Colorectal cancers exhibit a continuum of traits that differ with their location in the large intestine. Due to anatomical and molecular differences, rectal cancer is treated differently from colon cancer, with neoadjuvant chemoradiotherapy playing a pivotal role in the control of the locally advanced disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!